US equities
|
MU
$1,088.00
▲+4.06%
NVDA
$237.47
▼-0.74%
SNDK
$1,692.42
▲+1.92%
SPCX
$167.60
▼-2.51%
AMD
$645.86
▼-0.55%
AAPL
$336.67
▲+0.91%
TSLA
$377.81
▼-0.75%
META
$721.31
▼-2.38%
MU
$1,088.00
▲+4.06%
NVDA
$237.47
▼-0.74%
SNDK
$1,692.42
▲+1.92%
SPCX
$167.60
▼-2.51%
AMD
$645.86
▼-0.55%
AAPL
$336.67
▲+0.91%
TSLA
$377.81
▼-0.75%
META
$721.31
▼-2.38%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Allarity Therapeutics, Inc. - Common stock
(NQ:
ALLR
)
0.9840
-0.0013 (-0.13%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Allarity Therapeutics, Inc. - Common stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit
February 26, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients
February 24, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
February 06, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC
January 30, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
November 18, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights
November 14, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
November 12, 2024
From
The Schall Law Firm
Via
Business Wire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
November 12, 2024
From
Faruqi & Faruqi, LLP
Via
Business Wire
ALLR DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
November 09, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
ALLR Deadline: Rosen Law Firm Urges Allarity Therapeutics, Inc. (NASDAQ: ALLR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
November 08, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Allarity Therapeutics, Inc. (ALLR)
November 08, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
November 06, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
ALLARITY ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm
November 05, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors of Allarity Therapeutics to Contact Us to Have Their Losses Evaluated Today
November 02, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
October 30, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GitLab, Allarity, ZoomInfo, and Agenus and Encourages Investors to Contact the Firm
October 29, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
October 26, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
October 23, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Allarity, Metagenomi, Agenus, and New Fortress and Encourages Investors to Contact the Firm
October 22, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib
October 22, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Allarity, Metagenomi, Paragon 28, and New Fortress and Encourages Investors to Contact the Firm
October 16, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
October 16, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
October 13, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
ROSEN, A LEADING NATIONAL FIRM, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
October 10, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
October 10, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Allarity, Metagenomi, Paragon 28, and New Fortress and Encourages Investors to Contact the Firm
October 09, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALLR
October 06, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Allarity, Metagenomi, Paragon 28, and New Fortress and Encourages Investors to Contact the Firm
October 05, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program
October 03, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Allarity, Metagenomi, and New Fortress and Encourages Investors to Contact the Firm
October 01, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
